Novel Treatments in Development for XXXX .

@entity1 @entity7971 @entity5 @entity320
The past several years can be considered a renaissance @entity7971 in the treatment of @entity320 . Following a 30-year stretch in which oncologists barely put a dent in a very grim overall survival (OS) rate for these @entity1 , things have rapidly changed course with the recent approval of three new @entity320 drugs by the FDA. Both oncogene-targeted therapy and immune checkpoint blockade approaches have shown remarkable efficacy in a subset of @entity320 @entity1 and have clearly been game-changers in terms of clinical impact. However, most @entity1 still succumb to their disease, and thus, there remains an urgent need to improve upon current therapies. Fortunately, innovations in molecular medicine have led to many silent gains that have greatly increased our understanding of the nature of @entity5 biology as well as the complex interactions between @entity5 and the immune system. They have also allowed for the first time a detailed understanding of an individual @entity1 's @entity5 at the genomic and proteomic level. This information is now starting to be employed at all stages of @entity5 treatment, including diagnosis, choice of drug therapy, treatment monitoring, and analysis of resistance mechanisms upon recurrence. This new @entity7971 of personalized medicine will foreseeably lead to paradigm shifts in immunotherapeutic treatment approaches such as individualized @entity5 vaccines and adoptive transfer of genetically modified T cells. Advances in xenograft technology will also allow for the testing of drug combinations using in vivo models, a truly necessary development as the number of new drugs needing to be tested is predicted to skyrocket in the coming years. This chapter will provide an overview of recent technological developments in @entity5 research, and how they are expected to impact future diagnosis, monitoring, and development of novel treatments for @entity320 .
